High-molecular-weight kininogen (HMWK) deficiency is a very rare hereditary disorder. We herein report a case of HMWK deficiency with splenic infarction. The HMWK activity of the proband was markedly decreased (0.9%). Direct sequencing of his HMWK gene showed a homozygous "TC" insertion at c523-524 in exon 4. This insertion led to an amino acid substitution, Ser175Ser, resulting in a frameshift mutation and a premature stop codon in amino acid 183. Furthermore, the HMWK activity was also reduced in the patient's three children, who exhibited the heterozygous "TC" insertion at c523-524 in exon 4. This is the first report of this gene alteration in a patient with HMWK deficiency.
Introduction
High-molecular-weight kininogen (HMWK) is a carrier of prekallikrein (PK) and factor XI. These factors form a complex that activates coagulation and fibrinolysis by adsorbing to anionic molecules. HMWK deficiency is a rare congenital disorder that is inherited in an autosomal recessive manner. Individuals with this condition typically exhibit an isolated, markedly prolonged activated partial thromboplastin time (APTT), while other coagulation screening tests are normal. The disorder is not associated with abnormal bleeding, even after surgery or traumatic injury. However, some reports suggest that HMWK deficiency contributes to thrombosis (1) (2) (3) . We herein report a case of HMWK deficiency diagnosed using direct sequencing of the kininogen-1 gene in a patient presenting with splenic infarction.
Case Report
A 67-year-old man presented with sudden pain in the left upper abdomen. Abdominal computed tomography identified splenic infarction (Fig. 1) . The patient did not have any of the common risk factors for thrombosis, such as hypertension, hyperlipidemia or atrial fibrillation. His blood cell count and serological findings were all within the normal ranges; however, his APTT was markedly prolonged (136.4 sec; normal control: 25.0-40.0 sec.) The results of screening tests for other coagulation factors, including lupus anticoagulant and fibrinolytic markers, were unremarkable, with the exception of a slightly reduced factor XI activity (69% were related to each other; however, the details were unclear and the parents were not cousins. The patient was administered aspirin and supportive treatment in the hospital, and his symptoms improved.
A mixing study to monitor circulating anticoagulant was performed as described by Exner et al. (4) , with a slight modification. Briefly, the patient's plasma was mixed with various final concentrations (0%, 10%, 20%, 50%, 80% and 90%) of normal plasma. The APTT values of the mixtures and normal control plasma were measured one minute after mixing and after two hours of incubation at 37 . The clotting time was measured using a CR-800 (Sekisui Medical, Tokyo, Japan) and KC-10 autoanalyzer (Heinrich Amelung, Lemgo, Germany). A pattern of deficiency was observed at both one minute and two hours after mixing. These results suggested that the prolongation in APTT was not due to the presence of lupus anticoagulant or clotting factor inhibitors.
The clotting activity of HMWK and plasma PK was measured as described by Komiyama et al. (5), with a slight modification. Briefly, APTT reagent containing Celite as an activator (APTT-STA, Sysmex, Kobe, Japan) was used in both assays to prevent excess activation of plasma PK and error due to the use of an inappropriate standard. One hundred microliters of plasma were diluted 20-fold with phosphate-buffered saline/0.1% bovine serum albumin and mixed with an equal volume of APTT reagent. The mixture was incubated at 37 for eight minutes in the HMWK assay and for one minute in the plasma PK assay. The clotting time was determined following the addition of 100 μL/25 mmoL/L of CaCl2. The data are expressed as the percent of the normal pooled plasma value. HMWK-deficient plasma was purchased from George King Bio-Medical (Overland Park, KS, USA), and PK-deficient plasma was purchased from HYPHEN BioMed (Neuville-Sur-Oise, France). The HMWK activity in the patient's plasma was markedly decreased (0.9%), while the PK activity was moderately decreased (28%) (Fig. 2a) .
To confirm the diagnosis of HMWK deficiency, we performed direct sequencing of all exons and exon-intron junctions. Genomic DNA was prepared from peripheral blood leukocytes using a QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA, USA). Each exon and exon-intron junction was amplified via polymerase chain reaction (PCR) using the primers described in Table 2 . The PCR products were directly sequenced using a Big-Dye Terminator Cycle Sequencing Kit and 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The initiating methionine was set to +1, and the amino acid residues of kininogen were numbered accordingly. The study was approved by the ethics committee of Saga University, and informed consent was obtained according to the Declaration of Helsinki. The gene analysis was performed at Mie University Graduate School.
The sequencing results showed a homozygous TC insertion between nucleotides 523 and 524 in exon 4, which encodes part of domain 2 (Fig. 2b) . This insertion, which occurs at the third position of the Ser175 codon, results in a frameshift mutation that causes a premature stop codon at position 183, thereby producing a truncated protein of only 182 amino acid residues. As the patient was homozygous for the same insertion mutation, it was possible to diagnose 
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5'-TTGTCCTTCCTCTCAAGGTTGCTG-3' him with inherited HMWK deficiency. We then analyzed the HMWK and plasma PK activity and investigated the presence of HMWK mutations in the proband's three offspring. Offspring 1, 2 and 3 exhibited a decreased HMWK activity (44%, 62% and 62%, respectively); however, their plasma PK levels were normal (Fig. 2a) . The heterozygous TC insertion at nucleotide position 523-524 in exon 4 was present in all three offspring (Fig. 2b) . None of the offspring had presented with a thrombotic disease at the time of this report.
Discussion
Since Saito et al. described the first case of HMWK deficiency, several other cases have been reported (6) ; however, only a few mutations in the kininogen-1 gene have been described. Deletions and point mutations, including changes resulting in total kininogen deficiency, have been reported at other sites in the kininogen gene, including exons 5 and 10 and introns 7 and 9 (7-10) ( Table 3 ). These mutations result in premature stop codons and the absence of mature kininogen. The mutation observed in the present patient, which also results in HMWK deficiency as a consequence of a premature stop codon, is the first TC insertion described in this exon 4 and induced the patient not to produce mature kini- Most HMWK deficiency patients exhibit a low PK activity (8, 9) , and the disorder is more prevalent in the general population than is currently thought. Gallimore et al. reported a greater prevalence of PK and HMWK deficiency in patients with a history of venous thrombosis than in healthy blood donors (2). Siegerink et al. reported an association between extreme levels of HMWK and ischemic stroke in young women (11) . HMWK deficiency is not associated with abnormal bleeding, despite the presence of a prolonged APTT; however, HMWK inhibits platelet adhesion and aggregation (12, 13) . The molecular phenotype observed in an APTT assay is not always physiologically reflected in the coagulation ability of the corresponding patient's blood, as proteins of the contact system are not key elements of the coagulation pathway. Rather, it is thought that they play a secondary role in the generation of thrombin and intrinsic fibrinolysis activation. This theory is given some credence by the finding that the first patient described with factor XII deficiency died as a result of pulmonary embolism (14) .
Our patient presented with splenic infarction and, upon an examination, demonstrated HMWK deficiency and a moderately decreased PK activity. Splenic infarction is often caused by factors promoting clot formation, such as infection, clotting disorders, hematological disorders and malignancy; however, our HMWK-deficient patient had none of these conditions or other thrombosis risk factors.
Mutational inactivation of HMWK may allow for platelet aggregation, leading to thrombosis, and thrombotic manifestations are thought to be a problem in patients with HMWK deficiency (1-3) . To the best our knowledge, kininogen deficiency-induced thrombosis has been reported in only two cases. In one case, a patient with total kininogen deficiency presented with deep venous thrombosis and pulmonary artery embolism (3, 15) . In the other case, a patient with HMWK deficiency presented with occlusion of the vertebral-basilar arteries (9) ( Table 3) . Two of three patients with thrombosis, including our patient, had a mutation in the region of domain 2. Domain 2 of the kininogen-1 protein is involved in the prevention of calpain-related platelet aggregation (15) , and the prevention of binding between thrombin and glycoprotein Ib-IX-V (GPIb-IX-V) via domain 3 or protease-activated receptor-1 activation via domain 4 also plays a role in the function of HMWK (16) . Deletion of domain 2 or later may more strongly induce thrombosis, although this issue remains unclear because no expression experiments or functional analyses were examined in this instance.
In conclusion, we discovered a novel mutation of the kininogen-1 gene in a HMWK-deficient patient who presented with splenic infarction. Further biochemical and clinical studies are needed to understand this disease and its inheritance and to fully clarify the role of HMWK deficiency in the etiology of thrombosis.
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